Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Liposarcoma 8Hemangiosarcoma 8Fibrosarcoma 8Lymphoma, Large B-Cell, Diffuse 7Sarcoma, Synovial 6Rhabdomyosarcoma 6Neurofibrosarcoma 6Malignant mesenchymal tumor 6Leukemia 6Leiomyosarcoma 6Histiocytoma, Malignant Fibrous 6Hemangiopericytoma, Malignant 6Testicular Neoplasms 5Teratoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Testicular Germ Cell Tumor 4Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Endodermal Sinus Tumor 4Seminoma 3Neuroblastoma 3Neoplasm Metastasis 3Lymphoma, Follicular 3Hodgkin Disease 3Carcinoma, Embryonal 3

Interventions

Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pleuropulmonary blastoma × Ifosfamide × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡